Regulus Therapeutics Inc.
Regulus Therapeutics is a clinical-stage biopharmaceutical company focused on microRNA-targeting drugs. They have a product candidate, RGLS8429, in Phase 1b trial for autosomal dominant polycystic kidney disease. The company also develops preclinical products for target organ-selective delivery strategies.
Overview
Strengths
- No significant strengths identified based on the analyzed metrics.
Weaknesses
- With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
- The company have lower returns than the sector in which it operates. ROIC (0.00%) is significantly lower than the sector mean (6.02%).
- EBITDA Margin (0.00%) appears relatively low.
Key Financial Data
| Indicator | Value |
|---|
| PER | 100.0 |
| EV/EBITDA | 100.0 |
| Price/Free Cash Flow' | 100.0 |
| ROIC | -% |
| Net Debt/EBITDA | 0.8 |